Experts Explore Ways to Strengthen Protection from Viral Contamination
This article was originally published in The Gold Sheet
Executive Summary
Adding viral barriers and testing can prevent shutdowns like Genzyme's - or create ones like Glaxo's. What is the right balance? WCBP symposium explores relative merits of treatment barriers and testing. The testing FDA's vaccines office recommends. The combination approach. FDA's advice for winning approval to add treatment barriers.
You may also be interested in...
ICH Revises Viral Safety Guideline For New Types Of Products, Processes And Methods
Draft rewrite issued for comment updates 20-year-old Q5A document with advice around new developments like the advent of viral vectors, continuous manufacturing and next-generation sequencing.
MIT Consortium Shares Secrets to Prevent Viral Contaminations
MIT provides way for biopharma to share learnings from adventitious agent contamination incidents anonymously. The goal is to better identify, correct and prevent viral and other contaminations.
Vaccines Face Unknown Contamination Risks, But Need Well-Defined Testing
The discovery of adventitious porcine virus in Merck's RotaTeq and GlaxoSmithKline's Rotarix is setting off a scramble among vaccine manufacturers and FDA to come up with validated procedures to detect and deal with such undesirable agents